لحد يقول مادريت الحق ليست توصية بل تخاريف

الموضوع في 'السوق الأمريكي للأوراق الماليه' بواسطة n y c, بتاريخ ‏2 ابريل 2006.

  1. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    السلام عليكم

    هذا سهم غريب وخبر عنه اغرب ومادري كيف افسر الحاله للسهم بس انتم ابخص ويقولون بالامثال عط الخباز خبزة ولو اكل نصة وانا اقولكم ان كانه شرعي وزين الله يرزقكم وتراي حاولت اعرف انه شرعي او لا ماقدرت
    ان شالله راح احط كم سهم والباقي عليكم

    هذا هو الخبر

    Spencer becomes world’s biggest currency dealer
    By Ian Watson and Ben Marlow
    02 April 2006


    MICHAEL Spencer’s ICAP has clinched a deal to acquire EBS, the world’s biggest currency and gold trading platform. Spencer has seen off fierce competition from rivals such as US stock market Nasdaq and UK broker-dealer Collins Stewart, The Business has learned.

    The deal will cement ICAP’s position as the world’s biggest inter-dealer broker and boost the City of London’s challenge to New York as the world’s leading financial services centre.

    Although Spencer would not comment, sources close to the talks said they confidently expect ICAP to confirm shortly that a deal has been agreed. ICAP is believed to be paying between $750m (£430m, E618m) and $800m, and was chosen as the preferred bidder ahead of strong interest from Collins Stewart, headed by Terry Smith.

    The purchase of EBS is a coup for Spencer and another transforming deal for ICAP, which bought US electronic brokerage BrokerTec for £180m in 2003. The BrokerTec deal gave ICAP market leadership in electronic bond trading between financial institutions. The powerful combination of EBS and BrokerTec will give ICAP a global pipeline of trading opportunities. It will push Spencer’s group far ahead of competitors such as Reuters, Collins Stewart and eSpeed in electronic trading.

    EBS has more than 2,000 traders executing an average of $125bn in spot foreign ex-change transactions daily, as well as 700,000 ounces of gold and 7m ounces of silver.
    The source said: “It’s a great coup for ICAP, and a great deal for the City of London. It makes ICAP a very powerful force in the world of electronic trading.”

    Spencer, ICAP’s founder, was one of the first City entrepreneurs to spot the oppor*tunities arising from global- isation and to identify electronic trading markets as a priority for expansion.

    The deal will come as a disappointment to ICAP’s arch rival Collins Stewart, which is also keen to expand into electronic broking but has chosen instead to develop its own platform. The group recently hired a head of trading technology from ICAP to help build the electronic trading side of the business.


    والغريب هذا السهم حطيت اسمة ICAP وتغير الى ITPC.PK:rolleyes:

    INTREPID CAP CP NEW (Other OTC:ITPC.PK) Delayed quote data

    Last Trade: 1.25
    Trade Time: Mar 15
    Change: 0.00 (0.00%)
    Prev Close: 250.00
    Open: N/A
    Bid: N/A
    Ask: N/A
    1y Target Est: N/A

    Day's Range: N/A - N/A
    52wk Range: N/A
    Volume: 0
    Avg Vol (3m): N/A
    Market Cap: 20.00K
    P/E (ttm): N/A
    EPS (ttm): -127.48
    Div & Yield: N/A (N/A)

    واللي فهمته ان الصفقة الا هذة اللحظة لم ينتهوا من الاجتماع

    وان شالله الاخوان مايقصرون ويفهمونا قصة هذا السهم

    والله ياخوفي يطلع محفظة واتفشل :D
    السهم الثاني بالطريق ان شالله
     
  2. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    هذة تكملة الخبر الله يكفينا شر النسيان :rolleyes:

    Spencer becomes world’s biggest currency dealer
    By Ian Watson and Ben Marlow
    02 April 2006


    Collins Stewart’s Smith is focusing efforts on plans to reshape the London headquartered company he co-founded. He plans to split the company into two separately listed parts, a move he argues will enhance shareholder value.

    Nasdaq will also be disappointed. Spencer’s triumph follows its abortive attempt to acquire the London Stock Exchange (LSE). The New York exchange made a non-binding offer for the LSE at the beginning of March and its interest in bidding ended last week when it withdrew after failing even to hold discussions with LSE directors.

    The EBS deal owes much to Spencer’s negotiating skills and his close relationships with the heads of the 13 banks that own EBS. Big EBS shareholders – including JP Morgan, Bank of America, Lehman Brothers, Barclays, Citigroup and Royal Bank of Scotland – were divided on some elements of the sale, making a final agreement difficult.

    The acquisition of EBS by a London-listed company will be celebrated in the City at a time when it is realistically challenging New York’s long-*standing status as the world’s pre-eminent financial centre.

    There has been a recent surge of M&A activity in the foreign currency trading sector. Many observers believe the increased interest upped the price ICAP had to pay for EBS, which was initially valued at $700m.

    US-based Knight Capital bought privately-held Hotspot FX earlier this year. FXAll, a currency trading portal owned by a similar consortium of banks to those owning EBS, is understood to have agreed to sell a 20% stake to Technology Cross Ventures (TCV), a US-based private equity firm.

    The deal values the firm at $300m, a significantly higher multiple to profits than previous deals. TCV is understood to have beaten off rival General Atlantic, which last year bought a 25% stake in forex specialist firm SaxoBank for $126.5m.
     
  3. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    نكمل هذة شركتين او شركة وحدة صار بينهم شي :D امحق تعبير

    والله اعلم
    هذا الاول

    CITY NETWORK INC (AMEX:CSN) Delayed quote data

    Last Trade: 0.18
    Trade Time: Mar 31
    Change: 0.02 (12.50%)
    Prev Close: 0.16
    Open: 0.16
    Bid: N/A
    Ask: N/A
    1y Target Est: N/A

    Day's Range: 0.16 - 0.18
    52wk Range: 0.11 - 0.42
    Volume: 7,900
    Avg Vol (3m): 27,271
    Market Cap: 5.93M
    P/E (ttm): N/A
    EPS (ttm): -0.00
    Div & Yield: N/A (N/A)



    وهذا الثاني

    COGNOS INC (NasdaqNM:COGN) Delayed quote data

    After Hours (RT-ECN): 38.92 0.02 (0.05%)

    Last Trade: 38.90
    Trade Time: Mar 31
    Change: 0.75 (1.97%)
    Prev Close: 38.15
    Open: 38.42
    Bid: 38.90 x 300
    Ask: 39.30 x 400
    1y Target Est: 41.12

    Day's Range: 37.99 - 39.57
    52wk Range: 31.56 - 43.65
    Volume: 5,148,631
    Avg Vol (3m): 1,132,720
    Market Cap: 3.52B
    P/E (ttm): 26.85
    EPS (ttm): 1.45
    Div & Yield: N/A (N/A)


    وهذا الخبر وركزوا على تواريخ الاخبار
    Friday, March 31, 2006 12:15:42 PM ET

    OTTAWA (Reuters) - A lower-than-expected profit forecast from Cognos Inc. <CSN.TO> <COGN.O> likely reflects caution from Canada's biggest software company, rather than weaker business prospects, several analysts said on Friday.

    Cognos blew by expectations with its fourth-quarter results after markets on Thursday, but issued a first-quarter profit estimate that analysts said was weaker than anticipated.

    Profit will be squeezed by a 4 cent per share foreign exchange hit and a 5 cent a share impact from expensing stock-based compensation.

    Cognos forecast first-quarter earnings between 15 cents and 19 cents a share, or 24 cents to 28 cents if adjusted for one-time impacts. Analysts expected earnings of 28.5 cents.

    Bruised by three warnings it issued in the last year, the Ottawa-based company's guidance is "overly conservative," said Canaccord Adams analyst Peter Misek.

    "If business intelligence is as much of a corporate priority as we believe it is, then the firm will beat on (first-quarter) percentages that could approach the (fourth-quarter) beat," he told Reuters.

    "As such, we are raising our estimates after evidence of traction with Cognos 8."

    Cognos makes business intelligence software, which analyzes vast stores of an organization's data to determine trends and help in decision making.

    It competes with such rivals as Business Objects SA <BOBJ.O> and Hyperion Solutions Corp. <HYSL.O> along with diversified software vendors such as Microsoft <MSFT.O> and Oracle <ORCL.O>.

    It had a rocky transition with the launch last year of its new software platform, Cognos 8, and results were further pinched by delays in closing large deals.

    Chief Executive Rob Ashe told analysts on Thursday that he plans to "aggressively" hire sales staff and boost those ranks from 351 to 370 at the close of the first quarter.

    That hiring plan suggests recovery from earlier problems, RBC Capital Markets analyst Mike Abramsky said.

    "Cognos' guidance is typically conservative and Q1 license (revenue) is likely to be stronger than expected," he said in a note. "Management affirmed that fiscal 2007 license (revenue) will grow faster than overall revenue."

    A new direct sales program for Cognos's top 125 customers is further proof of demand, said Montgomery & Co. analyst John Torrey.

    Cognos 8, in its first full quarter of availability, made up $55.5 million of first-quarter license sales of $117.9 million.

    "Cognos 8 has started to deliver and we expect reinvigorated license growth," said UBS analyst Robert Dennison in a note.

    Scotia Capital analyst Paul Steep downgraded the stock to "2 sector perform" from "1 sector outperform" because the shares are approaching fair value. He also cut the target price to $42 from $45, citing his estimates for lower earnings and higher sales organization costs.

    "Our more tempered view is based on the ongoing execution risk inherent in the reorganization of the firm's salesforce," Steep wrote.

    In contrast, Friedman, Billings, Ramsey analyst David Hilal raised his stock target to $45 from $42 and maintained an "outperform" rating. He expects that Cognos 8 will "be hitting its sweet spot over the coming quarters."

    Cognos shares were up less than 1 percent on Friday to $38.37 on Nasdaq and C$44.73 on the Toronto


    الله يرزقكم ان كان فيها خير لكم وانا اتوقع انه شرعي عطاني يد خضراء
    :D
     
  4. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    وخذ عندك هذا الخبر

    والظاهر انه شرعي عطاني يد خضراء

    TEVA PHARM INDS AD (NasdaqNM:TEVA) Delayed quote data

    After Hours (RT-ECN): 41.00 0.18 (0.44%)

    Last Trade: 41.18
    Trade Time: Mar 31
    Change: 0.32 (0.78%)
    Prev Close: 40.86
    Open: 40.86
    Bid: 40.00 x 200
    Ask: 41.36 x 1000
    1y Target Est: 47.13

    Day's Range: 40.77 - 41.35
    52wk Range: 29.50 - 45.91
    Volume: 2,410,587
    Avg Vol (3m): 5,061,350
    Market Cap: 25.56B
    P/E (ttm): 25.95
    EPS (ttm): 1.59
    Div & Yield: 0.29 (0.70%)


    وهذا الخبر وفية خبر ان البنك استلم معونة تقريبا هذا الي فهمته من الحومة الامريكية لدعم هذة الشركة سالفة طويلة اقروا وانشالله نتعاون ونشوف افضل شركة

    Teva Announces Approval of Deferoxamine Mesylate for Injection USP
    Sunday April 2, 10:40 am ET


    JERUSALEM--(BUSINESS WIRE)--April 2, 2006--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA - News) announced today that the U.S. Food and Drug Administration has granted approval for the Company's ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial. Shipment of this product will begin immediately.

    Teva's Deferoxamine Mesylate for Injection is the AP-rated generic equivalent of Novartis' Desferal® for Injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.

    Total annual sales of Deferoxamine Mesylate for Injection are approximately $43 million.

    Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90% of Teva's sales are in North America and Europe.

    Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final court decision, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.



    وهذا بعد زووود الله يبارك فيكم اذا كان السهم له علاقة باسرائيل ابلغونا
    Principles (GAAP). Other Israeli companies with ADRs are Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and NICE Systems (Nasdaq: NICE; TASE: NICE).

    The Bank of New York will administer Bank Hapoalim’s ADR program.



    والله يرزقنا ويرزقكم ان كان فية خير
     
  5. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    وخذ عندك الشركة هذة اعلنوا ارباح للربع الرابع او شي من هــ القبيل
    وقبل شوي منزلين خبر بس ماعرفت اجيبة
    اصحاب الخبرة افيدونا

    GAMING PARTNERS INTL (NasdaqNM:GPIC) Delayed quote data

    Last Trade: 15.83
    Trade Time: Mar 31
    Change: 0.42 (2.58%)
    Prev Close: 16.25
    Open: 16.20
    Bid: 16.61 x 1000
    Ask: 21.55 x 100
    1y Target Est: 22.08

    Day's Range: 15.08 - 16.20
    52wk Range: 8.92 - 25.54
    Volume: 29,687
    Avg Vol (3m): 29,825.8
    Market Cap: 124.58M
    P/E (ttm): 36.81
    EPS (ttm): 0.43
    Div & Yield: 0.10 (0.60%)

    وهذا الخبر والخبر طويل يمكن يثقل الصفحة :rolleyes:

    LAS VEGAS, March 31 /PRNewswire-FirstCall/ -- Gaming Partners International Corporation (Nasdaq: GPIC - News) today announced that net income for the fourth quarter ended December 31, 2005 posted a 67% increase on a 23% improvement in revenues. For the full year, net income climbed 66% on a 28% increase in revenues.

    والله يرزقنا ويرزقكم ان كان فية خير

    وان شالله نكمل
     
  6. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    وخذ عندك خبر او راي محلل يتوقعون ان السهم رخيص والمفروض سعرة يكون اكبر بكثير من هذا السعر وعليكم الباقي والله اعلم اذا كنت غلطان علموني يااهل الخبرة



    Microsoft stock alluring despite product delays: Barron‘s
    Staff and agencies
    02 April, 2006 هذا التاريخ





    25 minutes ago قبل

    NEW YORK - The quality of new products and a strategy to promote them make shares in Microsoft Corp (Nasdaq:MSFT - news) an attractive bet despite a delay in rolling out its Windows Vista and Office 2007, Barron‘s April 3 edition said.

    The report quoted Microsoft Chief Executive Steve Ballmer as saying the company saw growth potential for the company in such new markets as Internet-based television and wireless communications. Overall, Ballmer sees enough room for Microsoft to benefit from double-digit revenue gains, the report said.

    Goldman Sachs analyst Rick Sherlund estimates that Microsoft shares are as much as 25 percent undervalued due to the potential growth opportunities, Barron‘s said.

    The business weekly noted in its report that Microsoft should report close to $14 billion in profit this year, nearly triple the $4.5 billion it earned in 1998, but has seen nearly no return on its shares in that time frame.

    Microsoft last month said it would delay the delivery date for its Vista and Office products until January 2007, sparking concern among personal computer makers over a softening of sales in the interim.

    Barron‘s said in its report that such delays were commonplace in the software industry and that the new products will be Microsoft‘s "most significant upgrade to its operating system since Windows 95 arrived more than a decade ago."

    Sherlund estimates that growth in Microsoft‘s "core client" segment, which includes Windows, should rise to 7.3 percent this year from 5.2 percent in fiscal 2005, then accelerate to 12.4 percent growth in 2007, followed by an 11.1 percent increase in 2008, Barron‘s said.

    Microsoft officials could not immediately be reached for comment.

    MICROSOFT CP (NasdaqNM:MSFT) Delayed quote data

    After Hours (RT-ECN): 27.24 0.03 (0.11%)

    Last Trade: 27.21
    Trade Time: Mar 31
    Change: 0.02 (0.07%)
    Prev Close: 27.23
    Open: 27.34
    Bid: 27.22 x 100
    Ask: 27.24 x 100
    1y Target Est: 31.21

    Day's Range: 27.21 - 27.54
    52wk Range: 23.94 - 28.38
    Volume: 62,367,591
    Avg Vol (3m): 62,460,500
    Market Cap: 281.17B
    P/E (ttm): 22.49
    EPS (ttm): 1.21
    Div & Yield: 0.36 (1.30%)



    والله يكتب لنا و لكم الرزق ان كان فية خير

    وان شالله اصحاب الخبرات يعلمونا المفيد
     
  7. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    هذة الشركة تقول تبي تعلن عن شي مهم قبل افتتاح السوق يوم الاثنين بكم ساعة والظظاهر انها ربحانة او عندة شي مهم تابعوها واللي عندة خبرة يعلمنا :rolleyes:

    Lipman Electronic Engineering Ltd. to Report First Quarter 2006 Financial Results on May 8, 2006; Webcast Scheduled for May 8, 2006
    ROSH HAAYIN, Israel--(BUSINESS WIRE)--April 2, 2006--Lipman Electronic Engineering Ltd. (Nasdaq: LPMA)(TASE: LPMA), a leading provider of electronic payment systems, will release first quarter 2006 financial results on Monday, May 8, 2006, during pre-market hours.


    The Company will conduct a conference call at 9:00 a.m. EDT on Monday, May 8, 2006 to discuss the first quarter 2006 results, which will be simultaneously webcast. The call will be hosted by Isaac Angel, Lipman's President and Chief Executive Officer, and Mike Lilo, Lipman's Chief Financial Officer.

    Investors are invited to listen to the call via a live webcast at the Lipman corporate web site at http://www.lipman.biz or at http://www.kcsa.com. Please visit the sites approximately twenty minutes before the conference call is scheduled to begin, as users will need to register as well as download and install any necessary audio software. A replay of the call will be available on the corporate web site approximately two hours after the conference is completed.

    About Lipman

    Lipman is a leading worldwide provider of electronic transaction systems and solutions. Lipman develops, manufactures and markets a variety of handheld, wireless and landline POS terminals, electronic cash registers, retail ATM units, PIN pads and smart card readers, as well as integrated PIN and smart card ("Chip & PIN") solutions. In addition, Lipman develops technologically advanced software platforms that offer comprehensive and customized transaction processing solutions for its customers, as well as managed professional services such as on-site and call-center support with remote terminal management.

    Lipman's corporate headquarters and R&D facilities are located in Israel. Lipman also maintains offices in the US, United Kingdom, Turkey, China, Spain, Finland, Russia, Italy, Canada, Brazil, Argentina, Mexico, Australia and India. For more information visit www.lipman.biz

    Statements concerning Lipman's business outlook or future economic performance; product introductions and plans and objectives related thereto; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under U.S. Federal securities laws. Forward-looking statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. These risks, uncertainties and factors include, but are not limited to: our dependence on distributors and customers; the competitive market for our products; market acceptance of new products and continuing products; timely product and technology development/upgrades and the ability to manage changing market conditions; manufacturing in Israel; compliance with industry and government standards and regulations; dependence on key personnel; possible business disruption from acquisitions; and other factors detailed in Lipman's filings with the U.S. Securities and Exchange Commission. Lipman assumes no obligation to update the information in this release.


    LIPMAN ELEC ENG (NasdaqNM:LPMA) Delayed quote data

    Last Trade: 27.20
    Trade Time: Mar 31
    Change: 0.27 (0.98%)
    Prev Close: 27.47
    Open: 27.41
    Bid: 13.52 x 100
    Ask: 42.06 x 100
    1y Target Est: 28.56

    Day's Range: 26.98 - 27.65
    52wk Range: 19.15 - 33.65
    Volume: 55,396
    Avg Vol (3m): 128,265
    Market Cap: 734.21M
    P/E (ttm): 37.21
    EPS (ttm): 0.73
    Div & Yield: N/A (N/A)


    وان شالله ان كان فية خير الله يكتب لنا ولكم الرزق

    ومزيدا من المتابعات ان شالله ولا تحرمونا من ارائكم بارك الله فيكم

    افيدونا
     
  8. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    وهذا بعد بس انا شفت الشمعة مدري هي زينة ولا لا على العموم نواصل

    معليش طويل الخبر :D تتعبون شوي

    افيدونا

    هذا الخبر

    Article Date: 02 Apr 2006 - 0:00am (UK)

    Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the companies submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the use of Rituxan® (Rituximab) as first-line treatment of previously-untreated patients with low-grade or follicular, CD20-positive, B-cell non_Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisone) or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy or following CVP chemotherapy in those patients who achieved a response of stable disease or better.

    The sBLA submission is primarily based on efficacy and safety data from two randomized, controlled studies of Rituxan in 644 previously-untreated patients. The first study was a Phase III trial in 322 patients with follicular, CD20-positive, B-cell NHL that met its primary endpoint of an improvement in progression-free survival when Rituxan was used in combination with CVP chemotherapy as compared to CVP chemotherapy alone.

    The submission also includes data from a Phase III trial of Rituxan given in a series of infusions over a two year period of time designed to evaluate efficacy and safety in 322 patients who had achieved a response or demonstrated stable disease to first-line CVP chemotherapy and who were then randomized either to receive Rituxan or observation. This study, E1496, a National Cancer Institute-sponsored intergroup trial led by the Eastern Cooperative Oncology Group, met its primary endpoint of an improvement in progression-free survival.

    Rituxan is already approved as a single agent for patients with relapsed or refractory, low-grade or follicular CD20-positive, B-cell NHL; Rituxan in combination with CHOP or other anthracycline-based chemotherapy was approved in February as first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL). Also in February, Rituxan was approved in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

    About Non-Hodgkin's Lymphoma

    An estimated 360,000 Americans have non-Hodgkin's lymphoma (NHL) and more than 58,000 new cases are diagnosed annually. Of those diagnosed with NHL, about 50 percent of patients have a slow-growing, but usually incurable (low-grade) form of the disease -- the most common type is called follicular lymphoma. The other 50 percent have a faster-growing subtype of NHL, which divides and multiplies rapidly in the body, and if left untreated, can be fatal.

    Rituxan Safety Profile

    The safety profile of Rituxan has been established in more than 730,000 patient exposures over a period of eight years.

    In non-Hodgkin's lymphoma, the majority of patients experience infusion-related symptoms with their first Rituxan infusion. These symptoms include but are not limited to: flu-like illness, fever, chills/rigors, nausea, urticaria, headache, bronchospasm, angioedema and hypotension. These symptoms vary in severity and generally are reversible with medical intervention.

    In general, the adverse events observed in patients with RA were similar in type to those seen in patients with NHL. The most common adverse events observed in patients treated with Rituxan in RA clinical trials were infusion reactions and infections. No significant change in average immunoglobulin levels was observed in Rituxan-treated patients in clinical trials. There was no increase in hematologic malignancies, demyelinating events or risk of opportunistic infections (including tuberculosis) in Rituxan-treated patients over 24 weeks of treatment. Although five percent of Rituxan-treated patients developed human anti-chimeric antibodies (HACA), this was not associated with loss of clinical response or additional safety observations.

    Severe infusion reactions have been reported in patients treated with Rituxan, some with fatal outcomes in patients with NHL. These severe reactions typically occur during the first infusion. The most severe manifestations and sequelae include pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, and anaphylactic and anaphylactoid events. Patients who develop clinically significant infusion reactions should have their Rituxan infusion discontinued and receive medical treatment. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in association with Rituxan treatment. Patients experiencing a severe mucocutaneous reaction should not receive any further infusions and seek prompt medical evaluation. Abdominal pain, bowel obstruction and perforation, in some cases leading to death, were observed in patients receiving Rituxan in combination with chemotherapy for diffuse large B-cell, CD20-positive, NHL. Other serious or potentially life-threatening adverse reactions that have been reported following Rituxan therapy include Hepatitis B reactivation with fulminant hepatitis, other viral infections, hypersensitivity reactions, and cardiac arrhythmias.

    About Rituxan

    Rituxan is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells without targeting stem cells or existing plasma cells. Rituxan is also being studied in other hematologic malignancies as well as autoimmune diseases with significant unmet medical needs, including systemic lupus erythematosus, lupus nephritis, multiple sclerosis and ANCA-associated vasculitis.

    Rituxan, discovered by Biogen Idec, received FDA approval in November 1997 for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma and in February 2006, Rituxan received FDA approval for the treatment of DLBCL in combination with CHOP or other anthracycline-based chemotherapy regimens in previously untreated patients. Also in February 2006, Rituxan in combination with MTX was approved to reduce signs and symptoms in adult patients with moderately-to-severely active RA who have had an inadequate response to one or more TNF antagonist therapies. It was approved in the European Union under the trade name MabThera®.

    Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets the drug as MabThera in the rest of the world, except Japan, where Rituxan is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. Rituxan is the top-selling oncology therapeutic in the United States. For a copy of the Rituxan full prescribing information, including Boxed Warnings, please call 1-800-821-8590 or visit http://www.gene.com.

    About Genentech

    Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

    About Biogen Idec

    Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare.

    وهذا زيادة

    BIOGEN IDEC INC (NasdaqNM:BIIB) Delayed quote data

    After Hours (RT-ECN): 47.16 0.06 (0.13%)

    Last Trade: 47.10
    Trade Time: Mar 31
    Change: 0.10 (0.21%)
    Prev Close: 47.20
    Open: 46.98
    Bid: 46.00 x 100
    Ask: 47.35 x 200
    1y Target Est: 50.56

    Day's Range: 46.64 - 47.39
    52wk Range: 33.18 - 50.72
    Volume: 2,174,452
    Avg Vol (3m): 3,569,790
    Market Cap: 16.21B
    P/E (ttm): 100.86
    EPS (ttm): 0.47
    Div & Yield: N/A (N/A)


    الله يرزقنا وياكم ان كان فية خير بانتظار الاخوه ليفيدونا
     
  9. sam-7

    sam-7 عضو جديد

    التسجيل:
    ‏19 فبراير 2006
    المشاركات:
    219
    عدد الإعجابات:
    0
    مكان الإقامة:
    الكويت
    مجهود طيب تشكر علية
     
  10. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    sam-7


    هلا اخوي منورنا وحياك الله

    وان شالله نكمل بعد اخذ قسطاً من الراحة للعيون:eek:
     
  11. راعي الذووود

    راعي الذووود عضو جديد

    التسجيل:
    ‏18 مارس 2006
    المشاركات:
    42
    عدد الإعجابات:
    0
    عساكم على القوه انشالله

    كل الشكر لكم ياخوان على هالتوضيح المفصل والكبير اللي انا شخصيا مافهمت منه شي :) لكن ولاعليكم امر اذا تعطوني رمز هالسهم اللي تكلمون عنه وتوضحون لي كم سعر الشراء وسعر البيع والمده المتوقعه وعسالله يجعلها في ميزان اعمالكم

    اخوكم اللي يحبكم في الله (ابو نوره)

    حكمه. :d اللي مايعرف الصقر لا يشويه يمكن مصاب بفلونزا الطيور :d
     
  12. tma215

    tma215 عضو جديد

    التسجيل:
    ‏15 فبراير 2006
    المشاركات:
    1,236
    عدد الإعجابات:
    0
    مكان الإقامة:
    الرياض
    جبت كل شيء عن الشركة ماقصرت اخوي
     
  13. me2withU

    me2withU عضو جديد

    التسجيل:
    ‏24 مارس 2006
    المشاركات:
    508
    عدد الإعجابات:
    0
    مكان الإقامة:
    مبارك الكبير
    يعطيك العافيه اخوي على هالخبريه

    بس رمز الشركه مو راضي يطلع حطيت icap مو راضي يطلع
    وحطيت itpk هم مو راضي
     
  14. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    السلام عليكم
    هلا بكم اخواني ومنورينا
    الحين راح نشوف الفرق بين اخبار البارح واسعار اليوم
    بسم الله

    الساعة 12 الظهر بتوقيت نيو يورك

    نبدا من الاخير

    السهم biib كان سعره 47.10
    والى الان Day's Range: 46.91 - 47.75

    السهم lpma كان سعرة 27.20
    والى الان Day's Range: 26.95 - 27.49

    السهم msft كان سعرة 27.21
    والى الان Day's Range: 27.46 - 27.73

    السهم gpic كان سعرة 15.83
    والى الان Day's Range: 16.93 - 18.00 :eek:

    السهم teva كان سعرة 41.18
    والى الان Day's Range: 41.25 - 41.98 :)

    السهم cogn كان سعرة 38.90
    والى الان Day's Range: 38.44 - 39.00 :cool:

    السهم csn كان سعرة 0.18
    والى الان 0.18 - 0.18:rolleyes:


    وانشالله تكون المتابعة حامية اليوم قبل تقفيل السوق

    me2withU هلا بك اخوي تقصد هذا ITPC.PK واذا كانك تقصد لحهؤ فانا كتبتها فوق واذا كان تقصد الثاني فكتبت تغير الاسم وهذا الشي الي انا مستغرب منه ومنورنا بزيارتك

    الساعة 12.22 وانشالله نتابع السوق
     
  15. n y c

    n y c عضو جديد

    التسجيل:
    ‏19 مارس 2006
    المشاركات:
    227
    عدد الإعجابات:
    0
    السلام عليكم

    ناسف للانقطاع والمتابعة البارح

    وان شالله نكمل اليوم المسيرة الاسبوعية للاسهم

    وفرق السعر قبل نزول الاخبار عنهم وبعد

    نبدا من الاخير

    السهم BIIB كان سعره 47.10
    والى الان Day's Range: 46.91 - 47.75 يوم 3 ابريل
    وسعر اليومDay's Range: 45.55 - 46.51 يوم 4 ابريل
    ......................................................................
    السهم lpma كان سعرة 27.20
    والى الان Day's Range: 26.95 - 27.49
    وسعر اليومDay's Range: 27.81 - 28.74 يوم 4 ابريل

    ..............................................................
    السهم msft كان سعرة 27.21
    والى الان Day's Range: 27.46 - 27.73
    وسعر اليوم Day's Range: 27.47 - 27.72 4 ابريل
    ......................................................................................
    السهم gpic كان سعرة 15.83
    والى الان Day's Range: 16.93 - 18.00
    وسعر اليومDay's Range: 17.21 - 17.46
    ....................................................................
    السهم teva كان سعرة 41.18
    والى الان Day's Range: 41.25 - 41.98
    وسعر اليوم Day's Range: 42.07 - 42.31 4 ابريل 4 ابريل
    ........................................................
    السهم cogn كان سعرة 38.90
    والى الان Day's Range: 38.44 - 39.00
    وسعر اليوم Day's Range: 37.97 - 38.66 4 ابريل

    السهم csn كان سعرة 0.18
    والى الان 0.18 - 0.18
    وسعر اليوم Day's Range: 0.16 - 0.18 4 ابريل

    وانشالله تكون المتابعة حامية اليوم قبل تقفيل السوق

    ملاحظة هذة الاسعر لليوم من بداية فتح السوق الى الساعة12.13 بتوقيت نيو يورك

    وان شالله نكمل اخر التطورات :D